ALLOZYNE
Allozyne develops and commercializes technologies that enable improvements in the efficacy, safety, dosing, and other characteristics of protein-based therapeutics, including peptides, antibodies, and vaccines. Its PEGylated IFN beta is for the treatment of multiple sclerosis. The company was founded in 2005 and is based in Seattle, Washington.
ALLOZYNE
Industry:
Biotechnology Health Care Therapeutics
Founded:
2005-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.allozyne.com
Total Employee:
11+
Status:
Active
Contact:
206-518-5700
Total Funding:
36.9 M USD
Technology used in webpage:
Viewport Meta Google Analytics Google Universal Analytics AJAX Libraries API U.S. Server Location Common Name Invalid PHP Sectigo SSL Sectigo Domain SSL Shockwave Flash Embed
Similar Organizations
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Current Advisors List
Board_member
Board_member
Current Employees Featured
Kenneth Grabstein CSO @ Allozyne
CSO
Founder
Investors List
OVP Venture Partners
OVP Venture Partners investment in Series B - Allozyne
Alexandria Real Estate Equities
Alexandria Real Estate Equities investment in Series B - Allozyne
Amgen Ventures
Amgen Ventures investment in Series B - Allozyne
MPM Capital
MPM Capital investment in Series B - Allozyne
ARCH Venture Partners
ARCH Venture Partners investment in Series B - Allozyne
MPM Capital
MPM Capital investment in Series A - Allozyne
ARCH Venture Partners
ARCH Venture Partners investment in Series A - Allozyne
Amgen Ventures
Amgen Ventures investment in Series A - Allozyne
OVP Venture Partners
OVP Venture Partners investment in Series A - Allozyne
Official Site Inspections
http://www.allozyne.com
- Host name: 115.130.96.66.static.eigbox.net
- IP address: 66.96.130.115
- Location: Burlington United States
- Latitude: 42.509
- Longitude: -71.1984
- Metro Code: 506
- Timezone: America/New_York
- Postal: 01803
More informations about "Allozyne"
Allozyne - Wikipedia
Allozyne was a clinical stage biotechnology company headquartered in Seattle's biotech and high tech innovation corridor. Allozyne was founded in 2005 by California Institute of Technology researchers, and was incubated by Accelerator Corporation. Its lead product candidate, AZ01, is a long acting interferon beta for the treatment of the relapsing remitting form of multiple sclerosis, a chronic de…See details»
Allozyne - Crunchbase Company Profile & Funding
Allozyne develops and commercializes technologies that enable improvements in the efficacy, safety, dosing, and other characteristics of protein-based …See details»
Allozyne 2025 Company Profile: Valuation, Investors, …
Allozyne General Information Description. Provider of protein therapeutic product candidates for the treatment of autoimmune and inflammatory diseases and …See details»
ALLOZYNE - LinkedIn
At ALLOZYNE, we demonstrate this through both of our technology platforms as well as across our pipeline to target key disease areas. Both of our platforms enable the incorporation of amino acid ...See details»
Allozyne, Inc. Company Profile | Seattle, WA - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Allozyne, Inc. of Seattle, WA. Get the latest business insights from Dun & Bradstreet.See details»
Allozyne Inc - Company Profile and News - Bloomberg Markets
Company profile page for Allozyne Inc including stock price, company news, executives, board members, and contact informationSee details»
Allozyne, Inc - VentureRadar
Allozyne is to modify at a specific site any protein sequence through the substitution or addition of non-natural amino acids, in E. coli, yeast or mammalian expression systems. Using these …See details»
ALLOZYNE Overview | SignalHire Company Profile
ALLOZYNE is a private company. The company currently specializes in the Biotechnology area. The position of the CEO is occupied by Meenu Chhabra ... Organization Website: …See details»
Allozyne - Funding, Financials, Valuation & Investors - Crunchbase
Allozyne develops technologies that improve the efficacy, safety, dosing, and other characteristics of protein-based therapeutics.See details»
Organization | Allozyne
Allozyne Report issue For profit Phase 2 Phase 3 Founded: Seattle WA United States (2005)See details»
Allozyne - Products, Competitors, Financials, Employees, …
Allozyne. Frequently Asked Questions (FAQ) When was Allozyne founded? Allozyne was founded in 2005. Where is Allozyne's headquarters? Allozyne's headquarters is located at 999 Third …See details»
Allozyne, Inc. Sold For Scrap As MedImmune Snaps Up Rights
Sep 19, 2014 The drug stays in a patient’s system longer and needs fewer doses, a boon to MS patients who have often have day-long infusion treatments. But Allozyne was competing in a …See details»
Allozyne, Inc. (Allozyne, Inc.) - 药物管线_专利_临床试验_投融营收
She also led the strategic merger with Yumanity Therapeutics. From 2007 to 2014, Ms. Chhabra Karson was President and CEO at Allozyne, Inc. Prior to her time at Allozyne, she served as …See details»
Allozyne company information, funding & investors | IAmsterdam …
Allozyne, allozyne develops technologies that improve the efficacy, safety, dosing, and other characteristics of protein-based therapeutics. Here you'll find information about their funding, …See details»
Allozyne, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Last update 09 Mar 2025. Allozyne, Inc. Private Company | Subsidiary Company |See details»
Allozyne, Inc - VentureRadar
Allozyne is to modify at a specific site any protein sequence through the substitution or addition of non-natural amino acids, in E. coli, yeast or mammalian expression systems. ... Dansk Biotek …See details»
Allozyne Management Team - CB Insights
Allozyne and VLST have successfully raised Series B rounds ($55M and $30M respectively) and have "graduated" from Accelerator. Prior to joining OVP, Carl was a Venture …See details»
Allozyne, Inc. Closes $30 Million Series B Financing ... - BioSpace
Oct 26, 2007 Dr. Michael Steinmetz, Executive Chairman of Allozyne and a General Partner at MPM Capital for BioVentures I, II, and III, as well as a Managing Director at Clarus Ventures, …See details»
Allozyne goes public via merger with Poniard | Fierce Biotech
Jun 23, 2011 Allozyne CEO Meenu Chhabra will head up the combined company. Poniard has been cutting staff and evaluating its options since 2009, when its cancer drug picoplatin …See details»
Biotech Allozyne Improving Protein Drugs With $30M Round
Oct 29, 2007 Two years after its launch by Seattle-based incubator Accelerator Corp., Allozyne Inc. is ready to move out on its own, thanks to a $30 million Series B round and the …See details»